TENAX THERAPEUTICS

Company snapshot

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies.

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for TENAX THERAPEUTICS. Not investment advice.

• Peer + 0 momentum

  United Therapeutics Europe

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for TENAX THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   TNX-103-07 — Phase 3

2. May 23, 2026 Clinical update

   Levosimendan — Phase 3

3. May 23, 2026 Clinical update

   TNX-103 — Phase 3

4. May 23, 2026 Clinical update

   TNX-103 — Phase 3

5. May 23, 2026 Clinical update

   Levosimendan — Phase 2

View all clinical trial activity →

• What is TENAX THERAPEUTICS?

  TENAX THERAPEUTICS is a pharma organization headquartered in Chapel Hill, USA. It trades on NYSE under ticker TENX. Primary therapeutic focus areas include Coronary Artery Bypass Grafting, Hypertension Pulmonary Secondary, Hypertension Pulmonary Secondary Heart Failure, Traumatic

• Is TENAX THERAPEUTICS publicly traded?

  Yes. TENAX THERAPEUTICS is listed with ticker TENX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does TENAX THERAPEUTICS develop or market?

  We link 2 drug profile(s) where TENAX THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tenax-therapeutics-inc#company-drugs.

• What are the latest developments for TENAX THERAPEUTICS?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does TENAX THERAPEUTICS focus on?

  TENAX THERAPEUTICS focuses on Coronary Artery Bypass Grafting, Hypertension Pulmonary Secondary, Hypertension Pulmonary Secondary Heart Failure based on our analysis of their pipeline programs and drug development activities.